PF-3882845（Cat No.:I008660）is a selective, orally bioavailable p38α mitogen-activated protein kinase (MAPK) inhibitor developed by Pfizer. By blocking p38α activity, it reduces the production of pro-inflammatory cytokines such as TNF-α and IL-1β, thereby modulating stress and inflammation-related signaling pathways. PF-3882845 has been investigated in preclinical and clinical studies for treating autoimmune and inflammatory diseases, including rheumatoid arthritis and chronic pain. Although development was discontinued, it remains valuable in research as a chemical probe to explore MAPK signaling, cytokine regulation, and potential therapeutic strategies for inflammation-driven disorders.